Last reviewed · How we verify
Amylase resistant starch added ORS
Amylase-resistant starch in oral rehydration solution reduces stool output and improves water absorption in diarrheal disease by providing a slowly fermentable carbohydrate substrate.
Amylase-resistant starch in oral rehydration solution reduces stool output and improves water absorption in diarrheal disease by providing a slowly fermentable carbohydrate substrate. Used for Acute diarrhea (cholera and non-cholera), Diarrheal disease in children.
At a glance
| Generic name | Amylase resistant starch added ORS |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | Oral rehydration therapy adjunct |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amylase-resistant starch (ARS) is a carbohydrate that resists enzymatic digestion in the small intestine and reaches the colon intact. There it undergoes bacterial fermentation, producing short-chain fatty acids (particularly butyrate) that enhance colonic water and electrolyte absorption. This mechanism reduces stool output and improves the efficacy of oral rehydration therapy in acute diarrhea.
Approved indications
- Acute diarrhea (cholera and non-cholera)
- Diarrheal disease in children
Common side effects
- Abdominal bloating
- Flatulence
- Mild abdominal discomfort
Key clinical trials
- Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: